Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study

Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study

Carfilzomib with dexamethasone (Kd) is a well-established regimen for the treatment of relapsed/refractory multiple myeloma (RRMM). There is limited information for the effects of Kd on myeloma-related bone disease. This non-interventional study aimed to assess skeletal-related events (SREs) and bon...

Full description

Bibliographic Details
Main Authors: Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Eirini Katodritou, Marie-Christine Kyrtsonis, Vassiliki Douka, Emmanouil Spanoudakis, Athanasios Papatheodorou, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Maria Gavriatopoulou, Polyzois Makras, Efstathios Kastritis, Meletios A Dimopoulos
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
multiple myeloma
carfilzomib
skeletal-related events
bone disease
bone metabolism
osteocalcin
Online Access:https://www.mdpi.com/2072-6694/13/6/1257

Internet

https://www.mdpi.com/2072-6694/13/6/1257

Similar Items